Literature DB >> 28880715

Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures.

B R Coyac1,2,3, B Hoac3, P Chafey4, G Falgayrac5, L Slimani1, P S Rowe6, G Penel5, A Linglart7,8, M D McKee3,9, C Chaussain1,7,10, C Bardet1.   

Abstract

X-linked hypophosphatemia (XLH) is a skeletal disease caused by inactivating mutations in the PHEX gene. Mutated or absent PHEX protein/enzyme leads to a decreased serum phosphate level, which cause mineralization defects in the skeleton and teeth (osteomalacia/odontomalacia). It is not yet altogether clear whether these manifestations are caused solely by insufficient circulating phosphate availability for mineralization or also by a direct, local intrinsic effect caused by impaired PHEX activity. Here, we evaluated the local role of PHEX in a 3-dimensional model of extracellular matrix (ECM) mineralization. Dense collagen hydrogels were seeded either with human dental pulp cells from patients with characterized PHEX mutations or with sex- and age-matched healthy controls and cultured up to 24 d using osteogenic medium with standard phosphate concentration. Calcium quantification, micro-computed tomography, and histology with von Kossa staining for mineral showed significantly lower mineralization in XLH cell-seeded scaffolds, using nonparametric statistical tests. While apatitic mineralization was observed along collagen fibrils by electron microscopy in both groups, Raman microspectrometry indicated that XLH cells harboring the PHEX mutation produced less mineralized scaffolds having impaired mineral quality with less carbonate substitution and lower crystallinity. In the XLH cultures, immunoblotting revealed more abundant osteopontin (OPN), dentin matrix protein 1 (DMP1), and matrix extracellular phosphoglycoprotein (MEPE) than controls, as well as the presence of fragments of these proteins not found in controls, suggesting a role for PHEX in SIBLING protein degradation. Immunohistochemistry revealed altered OPN and DMP1 associated with an increased alkaline phosphatase staining in the XLH cultures. These results are consistent with impaired PHEX activity having local ECM effects in XLH. Future treatments for XLH should target both systemic and local manifestations.

Entities:  

Keywords:  PHEX; collagen scaffold; extracellular matrix; osteopontin; proteins; tooth

Mesh:

Substances:

Year:  2017        PMID: 28880715      PMCID: PMC6429567          DOI: 10.1177/0022034517728497

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  35 in total

1.  SHED: stem cells from human exfoliated deciduous teeth.

Authors:  Masako Miura; Stan Gronthos; Mingrui Zhao; Bai Lu; Larry W Fisher; Pamela Gehron Robey; Songtao Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

2.  Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression.

Authors:  Xiuying Bai; Dengshun Miao; Dibiyendu Panda; Scott Grady; Marc D McKee; David Goltzman; Andrew C Karaplis
Journal:  Mol Endocrinol       Date:  2002-12

3.  Mineralized tissue cells are a principal source of FGF23.

Authors:  Yuji Yoshiko; Hua Wang; Tomoko Minamizaki; Chise Ijuin; Ryoko Yamamoto; Setsuko Suemune; Katsuyuki Kozai; Kazuo Tanne; Jane E Aubin; Norihiko Maeda
Journal:  Bone       Date:  2007-02-08       Impact factor: 4.398

4.  Pathogenic role of Fgf23 in Hyp mice.

Authors:  Shiguang Liu; Jianping Zhou; Wen Tang; Xi Jiang; David W Rowe; L Darryl Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-01-31       Impact factor: 4.310

5.  Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.

Authors:  Reinhold G Erben; Dagmar Mayer; Karin Weber; Kenneth Jonsson; Harald Jüppner; Beate Lanske
Journal:  J Bone Miner Res       Date:  2005-02-21       Impact factor: 6.741

6.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

Authors:  Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

7.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

8.  Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect.

Authors:  B Ecarot; F H Glorieux; M Desbarats; R Travers; L Labelle
Journal:  J Bone Miner Res       Date:  1992-02       Impact factor: 6.741

Review 9.  FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.

Authors:  L Darryl Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-07       Impact factor: 4.310

10.  Involvement of the klotho protein in dentin formation and mineralization.

Authors:  Hironobu Suzuki; Norio Amizuka; Kimimitsu Oda; Masaki Noda; Hayato Ohshima; Takeyasu Maeda
Journal:  Anat Rec (Hoboken)       Date:  2008-02       Impact factor: 2.064

View more
  8 in total

1.  Vitamin D and Phosphate Interactions in Health and Disease.

Authors:  Nuraly S Akimbekov; Ilya Digel; Dinara K Sherelkhan; Mohammed S Razzaque
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Vibrational spectroscopic analysis of hydroxyapatite in HYP mice and individuals with X-linked hypophosphatemia.

Authors:  Eva Amenta; Helen E King; Holger Petermann; Vuk Uskoković; Steven M Tommasini; Carolyn M Macica
Journal:  Ther Adv Chronic Dis       Date:  2018-10-11       Impact factor: 5.091

3.  Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study.

Authors:  Takuo Kubota; Seiji Fukumoto; Hae Il Cheong; Toshimi Michigami; Noriyuki Namba; Nobuaki Ito; Shin Tokunaga; Yoshimi Gibbs; Keiichi Ozono
Journal:  BMJ Open       Date:  2020-06-29       Impact factor: 2.692

4.  Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations.

Authors:  Douglas Chesher; Michael Oddy; Ulpee Darbar; Parag Sayal; Adrian Casey; Aidan Ryan; Annalisa Sechi; Charlotte Simister; Aoife Waters; Yehani Wedatilake; Robin H Lachmann; Elaine Murphy
Journal:  J Inherit Metab Dis       Date:  2018-02-19       Impact factor: 4.982

5.  Priming Dental Pulp Stem Cells from Human Exfoliated Deciduous Teeth with Fibroblast Growth Factor-2 Enhances Mineralization Within Tissue-Engineered Constructs Implanted in Craniofacial Bone Defects.

Authors:  Anita Novais; Julie Lesieur; Jérémy Sadoine; Lotfi Slimani; Brigitte Baroukh; Bruno Saubaméa; Alain Schmitt; Sibylle Vital; Anne Poliard; Christophe Hélary; Gaël Y Rochefort; Catherine Chaussain; Caroline Gorin
Journal:  Stem Cells Transl Med       Date:  2019-04-23       Impact factor: 6.940

Review 6.  Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives.

Authors:  Adalbert Raimann; Gabriel T Mindler; Roland Kocijan; Katrin Bekes; Jochen Zwerina; Gabriele Haeusler; Rudolf Ganger
Journal:  Wien Med Wochenschr       Date:  2020-01-28

7.  Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy.

Authors:  Rafi Brener; Leonid Zeitlin; Yael Lebenthal; Avivit Brener
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-15       Impact factor: 6.055

Review 8.  Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review.

Authors:  S Giannini; M L Bianchi; D Rendina; P Massoletti; D Lazzerini; M L Brandi
Journal:  Osteoporos Int       Date:  2021-05-19       Impact factor: 4.507

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.